News

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths
Drugmaker Sarepta Therapeutics said it won’t comply with a request from the FDA to halt all shipments of its gene therapy ...
Gene-therapy company to eliminate 21 Durham employees as part of major restructuring
Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says
The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...
Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments
The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...
Precision Medicine Online1d
Sarepta Shares Drop on Reports of Patient Death in Gene Therapy Trial
A 51-year-old man with limb-girdle muscular dystrophy died after receiving Sarepta's experimental gene therapy and experiencing acute liver failure.
STAT1d
Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
Sarepta shares sink on 3rd patient death amid restructuring statement
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news on Sarepta following a patient death.
Becker's Hospital Review1d
Sarepta reports 3rd patient death after gene therapy treatment
A third patient has died from acute liver failure after receiving a gene therapy treatment from Sarepta Therapeutics, the biotech company confirmed to Bloomberg on July 18. The patient died while ...
Fierce Biotech1d
UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Southwest Journal1d
Breaking: Second Patient Death Prompts FDA Investigation of Sarepta’s Elevidys Gene Therapy
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
Investor's Business Daily on MSN2d
Sarepta Catapults 20% On Restructuring Plans In The Wake Of Two Patient Deaths
Sarepta stock catapulted Thursday after the company announced a restructuring that includes 500 layoffs in the wake of two ...
Sarepta Therapeutics' Reorganization Boosts Investor Confidence
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...